<DOC>
	<DOCNO>NCT00313339</DOCNO>
	<brief_summary>Following Heart attack acute loss heart muscle cell result cascade event cause immediate decrease cardiac function potential persist long term . Despite revascularization infarct relate artery circulation appropriate medical management minimize stress heart wall , significant percentage patient experience permanent cardiac dysfunction consequently remain increased life-time risk experience adverse cardiac event , include death . There great potential stem cell therapy , use variety cell precursor ( particularly hematopoietic , ) contribute new blood vessel formation ( possibly limit heart muscle formation ) muscle preservation myocardial infarct zone . The administration cell via infusion infarct relate artery appear feasible result clinical effect study . Therefore , propose evaluate safety efficacy CD34+ select stem cell product ( AMR-001 ) , administer infarct relate coronary artery 6 9 day successful infarct related artery stent placement . The primary objective study determine feasibility safety prospectively identify patient risk clinically significant cardiac dysfunction follow myocardial infarction ability isolate infuse via affected coronary circulation autologous bone marrow derive CD34+ cell product four dose level . The secondary objective study assess effect cardiac function infarct region perfusion . A concurrent patient group meeting eligibility receive CD34+ cell evaluate similar treat group ass rate significant spontaneous improvement cardiac function without CD34+cell infusion .</brief_summary>
	<brief_title>Intra-coronary Infusion Bone Marrow Derived Autologous CD34+ Selected Cells Patients With Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Age 18 75 year . Acute ST elevation myocardial infarction meeting ACC/AHA criterion , symptom chest pain within 3 day admission . Criteria include ( ST elevation &gt; 1mm limb lead 2 mm two precordial lead increase level troponin , CPK MB ) NYHA heart failure class I , II III Patients candidate percutaneous intervention , conscious sedation , MRI , SPECT image minibone marrow harvest History sustain chest pain unrelieved nitrate , occur 4 day revascularization . Patients fail reperfuse infarct relate coronary artery successful stent placement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>myocardial infarction</keyword>
	<keyword>bone marrow</keyword>
	<keyword>cd34+</keyword>
	<keyword>stem cell</keyword>
</DOC>